Shannon E Boye

Shannon E Boye

Associate Professor, Associate Division Chief – Cellular And Molecular Therapeutics

Department: MD-PEDS-CELL / MOLEC THERP DIV
Business Phone: (352) 273-9342
Business Email: shaire@ufl.edu

About Shannon E Boye

Dr. Shannon E. Boye received her B.S. in marine biology with a minor in chemistry from Fairleigh Dickinson University in 2001. She graduated with a Ph.D. in Neuroscience from the University of Florida in 2006. Her thesis work involved developing viral vectors for the treatment of retinal disease, specifically GUCY2D Leber Congenital Amaurosis (LCA1). Following a postdoctoral fellowship and research assistant professorship under Dr. William Hauswirth, Dr. Boye was appointed as tenure track Assistant Professor in the University of Florida’s Department of Ophthalmology (2012). In 2016, she received tenure and was promoted to the rank of Associate Professor. In 2020, she transferred to the Department of Pediatrics where she is now Associate Chief of the Division of Cellular and Molecular Therapeutics.

Dr. Boye’s memberships in professional societies include the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Gene and Cell Therapy (ASGCT). She currently serves as PI, Co-PI or Co-Investigator on several federally as well as privately funded grants and is actively involved in the University of Florida’s teaching mission. She is actively engaged in community outreach and is a highly sought after speaker at patient-oriented conferences. Her real passion is interfacing with those affected by the diseases she studies and educating these individuals about treatment options and ongoing research to develop future treatments. For her efforts, she is the three-time recipient of the Exemplary Teacher Award from UF’s College of Medicine. She has authored over 50 peer-reviewed manuscripts, multiple textbook chapters, is actively involved in grant and manuscript review, and is the recipient of several major awards including the ARVO Foundation/Merck Innovative Ophthalmology Research Award in Gene Therapy and Eye Disease, the Foundation Fighting Blindness Board of Director’s Award, a UF Term Professorship, and the Gund Harrington Scholar Award for excellence in gene therapy research.

When she is not at work, Dr. Boye still spends most of her time in the ‘Wet Lab’ (our nerdy boat name) with her husband and two young children.

Accomplishments

UF Research Foundation Professorship
2019 · University of Florida
Pfizer Carl Camras Translational Research Award
2018 · ARVO Foundation
Exemplary Teacher Award
2018 · University of Florida
Exemplary Teacher Award
2017 · University of Florida
Scholar Award
2017 · Gund Harrington
University Term Professorship
2017 · University of Florida
Visionary Award
2016 · MOMS for Sight 2016
Board of Director's Award
2015 · Foundation Fighting Blindness
Nominee for Life Sciences Category for the Blavatnik Awards for Young Scientists
2015 · University of Florida
Exemplary Teacher Award
2014 · University of Florida
Travel Fellowship
2014 · XVIth International Symposium on Retinal Degenerations
Merck Innovative Ophthalmology Research Award in Gene Therapy and Eye Disease Price
2013 · ARVO Foundation
IOVS
2013 · Exceptionally Good Review ranking
Early Career Reviewer Program
2012 · National Institute of Health
Pediatric Loan Repayment Award Renewal
2012 · National Institute of Health
Pediatric Loan Repayment Award Renewal
2010 · National Institute of Health
Pediatric Loan Repayment Award
2008 · National Institute of Health
Grant Awardee
2006 · T32 Vision Research Training
Office of Naval Research
2002 · Enterprise Fellowship
Alumni Fellowship
2001-2005 · University of Florida's College of Medicine

Research Profile

The focus of my research is developing viral vector-based gene therapies for the treatment of inherited ocular disease. My current focus areas are:

1. to develop AAV-based gene therapy approaches for delivery of genes to the outer retina (notably foveal cones) 2. to develop an Adeno associated virus (AAV)-based gene therapy for treatment of autosomal recessive GUCY2D-Leber congenital amaurosis-1 (LCA1) 3. to develop dual AAV vector platforms that are capable of delivering large transgenes (> 5kb) 4. to develop a AAV-CRISPR/Cas9-based therapies for dominant inherited retinal disease 5. to develop AAV-based gene therapy approaches for delivery of genes to the trabecular meshwork to address treatments for primary open angle glaucoma

I have extensive experience characterizing animal models of inherited retinal disease, developing novel AAV vectors via both rational design and directed evolution, and testing these vectors for their ability to deliver genes to animal models of retinal disease. The work my team conducted over the last 15 years established that gene replacement restores retinal function/visually guided behavior, and preserves retinal structure over the long term in models of autosomal recessive LCA1. As a result, the FDA approved our initiation of PhaseI/II trials to treat patients afflicted with this devastating form of blindness (clinical trials began in fall 2019). I have three awarded patents, and eight pending patents emanating from my research program and am actively funded by the NIH, private foundations, and pharma. I am the recipient of several major awards including the Foundation Fighting Blindness’s Board of Director’s Award, the Gund Harrington Scholar Award, the ARVO Foundation/Merck Innovative Ophthalmology Research Award, and the ARVO/Pfizer Carl Camras Translational Research Award. Since 2010, I have given over 60 invited lectures both within and outside the USA. I have served as a member of study sections both for the NIH and the Department of Defense. I was the recipient of the NIH’s Loan Repayment Award, currently serve as an LRP ambassador and serve on study sections to review new proposals to this grant mechanism. I perform grant review for various other national and international foundations, serve on the editorial advisory board for multiple journals and perform ad hoc peer review for many more. I have participated in workshops including the NIH’s Office of Science Policy/Office of Biotechnology Activities “Gene Therapy: Charting a Future Course”. Outside of my research, I am actively involved in the teaching mission of the Department of Ophthalmology and College of Medicine at the University of Florida and am passionate about outreach/education outside the University. I routinely provide lab tours for visually impaired patients, host foundation meetings and educate patients about ongoing research being conducted to address treatments for their conditions/provide them with information on how to find out more about their disease.

Publications

2020 Molecular Therapy : The Journal Of The American Society Of Gene Therapy
2018 Molecular Therapy : The Journal Of The American Society Of Gene Therapy
2016 Advances in Experimental Medicine and Biology
2014 Advances in Experimental Medicine and Biology
2014 Cold Spring Harbor Perspectives in Medicine

Grants

Apr 2020 ACTIVE
Task Order #1 – AAV-hRS1 Pharmacology
ATSENA THERAPEUTICS · Principal Investigator
Apr 2020 ACTIVE
Task Order #2 – Dual AAV-MYO7A Candidate evaluation in Myo7a KO mice
ATSENA THERAPEUTICS · Principal Investigator
Sep 2019 ACTIVE
A Ribozyme Rescue Strategy for Autosomal Dominant Retinitis Pigmentosa
UNIV OF BUFFALO · Principal Investigator
Sep 2019 ACTIVE
Engineering AAV for safe and efficient gene delivery to the human retina
NATL INST OF HLTH NEI · Principal Investigator
Sep 2019 ACTIVE
Vascular gene delivery and early disease biomarkers in diabetic retinopathy
MEDICAL COLLEGE OF WISCONSIN · Principal Investigator
Jun 2019 ACTIVE
DEVELOPMENT OF AAV-CRISPR/CAS9-BASED THERAPIES FOR CONE ROD DYSTROPHY
NATL INST OF HLTH NEI · Principal Investigator
Jun 2019 ACTIVE
Enhancing Metabolism in Photoreceptors with a Modified Arrestin to Treat Retinal Degeneration
FOU FOR FIGHTING BLINDNESS · Project Manager
Apr 2019 ACTIVE
Dual AAV vector-mediated therapy for MyosinVIIa Usher syndrome (USH1B)
FOU FOR FIGHTING BLINDNESS · Principal Investigator
Sep 2018 – Aug 2019
Vascular gene delivery and early disease biomarkers in diabetic retinopathy
MEDICAL COLLEGE OF WISCONSIN · Principal Investigator
Sep 2018 – Dec 2019
Exploring MYO7A function in novel mouse models and improving AAV-Dual Vector Gene Therapy for Usher Syndrome 1B
NATL INST OF HLTH NEI · Mentor
Sep 2018 – Mar 2019
Developing a dual AAV vector gene therapy for the treatment of Usher syndrome
HARRINGTON DISCOVERY INSTITUTE · Principal Investigator
Nov 2017 – Dec 2019
Cas9 mediated gene editing therapy for CORD6 cone rod dystrophy/Extension of Sponsored Research Agreement btw Editas Medicine and the University of Florida
EDITAS MEDICINE · Principal Investigator
Aug 2017 ACTIVE
Optimizing AAV Vectors for Central Nervous System transduction
NATL INST OF HLTH NINDS ·
May 2017 ACTIVE
Therapy development for open-angle glaucoma
MICHIGAN STATE UNIV · Principal Investigator
Jan 2016 – Jun 2018
Cas9 mediated in vivo gene editing of photoreceptors in
EDITAS MEDICINE · Principal Investigator
Dec 2015 ACTIVE
miscellaneous donors
MISCELLANEOUS DONORS · Principal Investigator
Dec 2015 – Nov 2017
AAV-mediated optogenetic gene therapy in bipolar cells
APPLIED GENETICS TECH CORP · Principal Investigator
Sep 2014 – Aug 2018
AAV Capsid Library Screening
APPLIED GENETICS TECH CORP · Project Manager
Aug 2014 – Feb 2017
Dual AAV vector-mediated therapy for Myosin7a Usher syndrome (USH1B)
FOU FOR FIGHTING BLINDNESS · Principal Investigator
Apr 2014 – May 2019
Developing efficient AAV vectors for photoreceptor targeting via the vitreous
NATL INST OF HLTH NEI · Principal Investigator
Mar 2014 – Dec 2018
Gene Therapy for LCA1
GENZYME CORP · Principal Investigator

Patents

Published May 2014
Dual-AAV Vector-Based Systems and Methods for Delivering Oversized Genes to Mammalian Cells
#US2014/0256802
Published February 2015
Methods and Compositions for Gene Delivery to On Bipolar Cells
#US2017/0007720
Published March 2015
Improved rAAV Vectors and Methods for Transduction of Photoreceptors and RPE Cells
#US2016/0369299
Published February 2016
rAAV Vector Compositions, Methods for Targeting Vascular Endothelial Cells and Use in Treatment of Type I Diabetes
#us2018/0057840
Published October 2017
rAAV-Guanylate Cyclase Compositions and Methods for Treating Leber's Congenital Amaurosis-1 (LCA1) (CON)
#US-2018-0100165
Issued November 2017
rAAV-Guanylate Cyclase Compositions and Methods for Treating Leber's Congenital Amaurosis-1 (LCA1)
#9,816,108

Education

Postdoctoral fellowship/ Ophthalmology and Gene Therapy
2006-2008 · University of Florida
Ph.D./ Neuroscience
2006 · University of Florida
BS/Marine Biology and Chemistry
2001 · Fairleigh Dickinson University

Contact Details

Phones:
Business:
(352) 273-9342
Emails:
Business:
shaire@ufl.edu